ClinicalTrials.gg
Not yet recruitingNCT07940582Updated Nov 17, 2026

A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity

A Phase 1 interventional study of NNC0721-5186 and Semaglutide in Overweight and Obesity, sponsored by Novo Nordisk A/S. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Obesity by Novo Nordisk A/S — 50 open to participants now, 68 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Planned enrollment
103rd of 168
102 · median 138
Started
2026
with 48 others
Phase 1
86 of 209
23 open now
Primary completion
2028-05
later than 41 of 67 live
Registered
208th of 209
by date

Among the 209 studies in Obesity by Novo Nordisk A/S, this one is the 103rd largest by planned enrollment of the 168 interventional ones that give a count, is one of 49 that started in 2026, is one of 86 in phase 1, reaches primary completion later than 41 of the 67 other live ones, and was the 208th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

50 of the 209 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

45 more — sign in →

By country, each count listing its studies:

All 50 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is being done to look at the safety and how the body takes up, breaks down and removes NNC0721-5186 in people living with overweight or obesity when compared to placebo. In the first 3 dosing groups, NNC0721-5186 will also be compared with semaglutide, a medicine already approved for weight management. Participants will either get NNC0721-5186, semaglutide, or placebo. Which treatment participants get is decided by chance.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 102 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female (sex at birth).
  2. Age 18 to 55 years (both inclusive) at the time of signing the .
  3. 25.0 to 39.9 kg/m\^2 (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
  4. Considered eligible based on the medical history, physical examination and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to study intervention(s) or related products.
  2. Previous randomisation in this study.
  3. More than one rescreening for this study.
  4. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  5. Current participation (signed ) in any other interventional clinical study.
  6. Exposure to an medicinal product within 30 days or five half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
  7. Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
  8. (HbA1c) greater than or equal to 6.5 percent (48 mmol/mol) at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    NNC0721-5186

    Participants will receive a single ascending subcutaneous dose of NNC0721-5186.

    Drug: NNC0721-5186

  • Active comparator
    Semaglutide

    Participants will receive a single ascending subcutaneous dose of semaglutide up to 3 doses.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive a single ascending subcutaneous dose of placebo matched to NNC0721-5186.

    Drug: Placebo (NNC0721-5186)

Interventions

  • DrugNNC0721-5186

    NNC0721-5186 is administered as a single subcutaneous injection.

  • DrugSemaglutide

    Semaglutide is administered as a single subcutaneous injection using a pen-injector.

  • DrugPlacebo (NNC0721-5186)

    Placebo is administered as a single subcutaneous injection matching NNC0721-5186.

07

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events (TEAEs)

    Measured in number of events.

    Time frame: From time of dosing (Day 1) to Day 36

Secondary outcomes

  1. AUC: Area under the NNC0721-5186 plasma concentration-time curve

    Measured in hours per nanomole per litre (h\*nmol/L).

    Time frame: From pre-dose (Day 1) to Day 36

  2. Cmax: Maximum observed NNC0721-5186 plasma concentration

    Measured in nanomoles per litre (nmol/L).

    Time frame: From pre-dose (Day 1) to Day 36

08

Study locations

1 site
  • [Legal] Altasciences Clinical Los Angeles, Inc. & Altasciences Professional Los Angeles, P.C.
    Cypress, California 90630, United States
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 18 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 13, 2026
Primary completionEst.
May 29, 2028
CompletionEst.
May 29, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07940582
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
May 29, 2028 (estimated)
Completion
May 29, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion